These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22920207)

  • 21. [Li-Fraumeni syndrome].
    Tsunematsu Y
    Nihon Rinsho; 2000 Jul; 58(7):1442-7. PubMed ID: 10921321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.
    Tabori U; Nanda S; Druker H; Lees J; Malkin D
    Cancer Res; 2007 Feb; 67(4):1415-8. PubMed ID: 17308077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
    Agarwalla PK; Dunn IF; Turner CD; Ligon KL; Schneider KA; Smith ER
    Pediatr Neurosurg; 2008; 44(6):501-8. PubMed ID: 19127094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
    Masciari S; Van den Abbeele AD; Diller LR; Rastarhuyeva I; Yap J; Schneider K; Digianni L; Li FP; Fraumeni JF; Syngal S; Garber JE
    JAMA; 2008 Mar; 299(11):1315-9. PubMed ID: 18349092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [When is it useful to look for TP53 germline gene mutations in families of oncology patients?].
    Trková M; Sedlácek Z
    Cas Lek Cesk; 2003; 142(4):220-5. PubMed ID: 12841124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New knowledge of Li-Fraumeni syndrome].
    Funato M; Kondo N
    Gan To Kagaku Ryoho; 2013 Feb; 40(2):148-53. PubMed ID: 23411951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer risks from germ line tumor suppressor gene mutations.
    Frebourg T; Malkin D; Friend S
    Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Li-Fraumeni syndrome and the p53 gene].
    Thoresen SO
    Tidsskr Nor Laegeforen; 1992 Mar; 112(7):887-9. PubMed ID: 1557756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.
    Trkova M; Prochazkova K; Krutilkova V; Sumerauer D; Sedlacek Z
    Cancer; 2007 Aug; 110(3):694-702. PubMed ID: 17567834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parent decision-making around the genetic testing of children for germline TP53 mutations.
    Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
    Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prenatal diagnosis in Li-Fraumeni syndrome.
    Avigad S; Peleg D; Barel D; Benyaminy H; Ben-Baruch N; Taub E; Shohat M; Goshen Y; Cohen IJ; Yaniv I; Zaizov R
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):541-5. PubMed ID: 15342977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
    Bendig I; Mohr N; Kramer F; Weber BH
    Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there anticipation in the age at onset of cancer in families with Li-Fraumeni syndrome?
    Trkova M; Hladikova M; Kasal P; Goetz P; Sedlacek Z
    J Hum Genet; 2002; 47(8):381-6. PubMed ID: 12181637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
    Wu CC; Shete S; Amos CI; Strong LC
    Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
    Nichols KE; Malkin D; Garber JE; Fraumeni JF; Li FP
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):83-7. PubMed ID: 11219776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 mutation and haplotype analysis of two large African American families.
    Hung J; Mims B; Lozano G; Strong L; Harvey C; Chen TT; Stastny V; Tomlinson G
    Hum Mutat; 1999; 14(3):216-21. PubMed ID: 10477429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.
    Bougeard G; Brugières L; Chompret A; Gesta P; Charbonnier F; Valent A; Martin C; Raux G; Feunteun J; Bressac-de Paillerets B; Frébourg T
    Oncogene; 2003 Feb; 22(6):840-6. PubMed ID: 12584563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.